Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this animal study, administering testosterone alongside a 5α-reductase inhibitor counteracted testosterone's effects on prostate enlargement while preserving its beneficial effects on muscle and bone.

This review discusses the incidence, prevalence, and risk factors for epidermal cancer and premalignant epidermal neoplasia, and it reports no new clinical findings.

This article reviews corrective repair methods for unsatisfactory hair transplant outcomes, including strategies for improving recipient and donor sites, but reports no new clinical results.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

This article discusses the increasing use of lifestyle drugs by healthy individuals to alter appearance or slow aging and emphasizes the need for doctors to consider side effects and contraindications, but it reports no new clinical findings.

This article presents a diagnostic case in the Journal of Small Animal Practice and reports no new research findings.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This review discusses erosive pustular dermatosis of the scalp, highlighting its wide variety of causes and multiple effective treatment options beyond high-potency topical steroids, and reports no new clinical results.

This study found that scalp melanoma often occurs in areas with androgenetic alopecia, and patients without alopecia might experience a later diagnosis due to hair coverage, leading to potentially worse outcomes.

This research observed that oral testosterone replacement therapy significantly increases cardiovascular risk, while effects of injected or transdermal therapy on cardiovascular risk were not significant, prompting further investigation into these methods.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study concluded that female androgenetic alopecia is common among Caucasian women, starting in their late 20s and peaking after age 50.

This study found that patients treated with dutasteride were significantly less likely to experience acute urinary retention and prostate-related surgeries compared to those treated with finasteride.

This study found that applying 2% Minoxidil lotion twice daily for four months improved hair diameter and density in individuals with eyebrow hypotrichosis, suggesting it is an effective and well-tolerated treatment; mild side effects like itching and burning were observed in 22.72% of participants.

This case report describes an elderly man with erosive pustular dermatosis of the scalp, who improved with potent topical corticosteroids followed by maintenance with topical tacrolimus.

This review evaluates the quality of alopecia areata-specific patient-reported outcome measures and suggests that more high-quality validation studies are needed to enhance their reliability and validity.

5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.

This study found that the perception of hair loss symptom relief shampoos has increased across various demographics, and that satisfaction with these products is linked to features like scalp anti-aging and hair root strengthening, indicating a consumer preference for specialized functional shampoos.

This case report of a 60-year-old male patient diagnosed with trichilemmal carcinoma, initially mistaken for a sebaceous cyst, highlights the importance of careful evaluation of atypical swellings for correct diagnosis and treatment.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This review article discusses the potential benefits of advanced nanocarrier- and microneedle-based transdermal drug delivery systems for treating skin diseases, but reports no new clinical results.

This study found that among men with androgenetic alopecia, the M-type pattern, either isolated or combined with others, was observed most frequently, using the BASP classification.

This article reviews the design and objectives of the Rotterdam Study, as well as summarizes major findings, without reporting new results.

This study found that specific genetic markers near the androgen receptor gene are significantly more common in men with male pattern baldness, suggesting a genetic component in its development.

This article outlines the rationale and design of the Rotterdam Study, summarizes its major findings, and updates its objectives and methods; it reports no new research results.

This article outlines the rationale, design, major findings, and updated objectives of the ongoing Rotterdam Study, without presenting new research data.

In this study, among patients undergoing chemotherapy for breast or gynecologic cancers, smell and taste functions significantly decreased but largely recovered three months post-treatment, with taxane-based regimens causing more severe taste disturbances.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found no significant genetic association between the 5α-reductase enzyme genes and male pattern baldness, suggesting a polygenic etiology rather than simple inheritance.